GC Biopharma006280.KS

About GC Biopharma

GC Biopharma, long known as Green Cross, is Korea's leading maker of plasma-derived medicines and one of its principal vaccine producers. The company fractionates blood plasma into therapies such as immunoglobulins and albumin, and its intravenous immunoglobulin product has secured approval for the U.S. market. Vaccine operations center on seasonal influenza shots produced at scale, with a history of supplying international health agencies. Additional lines include recombinant therapies and treatments for rare diseases. GC Biopharma anchors the GC group, a family-led health-care conglomerate with a listed holding company above it, and earns revenue from domestic sales, exports, and institutional tenders.

Plasma economics shape the structural view: raw plasma must be collected or purchased, and its cost and availability move independently of drug prices, widening or squeezing spreads in ways investors monitor. Entry into the U.S. immunoglobulin market makes commercial execution there, spanning distribution, insurer coverage, and competition with global fractionators, a defining variable that shifts the company toward dollar-denominated exports. Vaccine revenue is seasonal and partly dependent on government procurement at home and abroad. The group's holding structure and family leadership frame the governance discussion, with affiliated companies in diagnostics and cell therapy adjacent.

Green Cross was established in 1967 with the goal of making medicines Korea could not yet produce, and it opened the country's first plasma fractionation plant in 1971. Landmark products followed, including one of the world's earliest hepatitis B vaccines in 1983 and a pioneering vaccine against hantavirus. A large influenza vaccine complex completed in South Jeolla province in 2009 made the company a significant supplier to international immunization programs. The company adopted the GC Biopharma name in 2022 as the group modernized its identity, and in 2023 its intravenous immunoglobulin won U.S. approval, opening the world's largest plasma market.

Plasma medicine has unusual economics that GC has mastered at home: each liter of plasma yields multiple products, immunoglobulin, albumin, and clotting factors, so profitability depends on selling the full slate rather than one therapy, and on securing plasma at reasonable cost. Vaccines run on a different rhythm, with seasonal influenza campaigns and tenders from governments and international agencies producing contract-driven, lumpy revenue. Hospital-channel strength supports domestic sales of recombinant and rare-disease therapies. The U.S. immunoglobulin entry pits GC against far larger multinational fractionators, where success depends on distribution partnerships and insurance coverage rather than manufacturing capability alone.

Company profile by LineVest editorial. Journalism, not investment advice. Commission a full DART-based report on GC Biopharma →